Effects of Bifidobacterium Tetrad adjuvant therapy on serum inflammatory factors and intestinal flora in patients with chronic hepatitis B cirrhosis
Objective To observe the effects of Bifidobacterium Tetrad as an adjuvant therapy on serum inflammatory factors and intestinal flora in patients with chronic hepatitis B(CHB)cirrhosis,providing a reference for the treatment.Methods A total of 100 patients with CHB cirrhosis admitted to our hospital from January 2022 to January 2023 were di-vided into control group(conventional treatment)and observation group(conventional treatment+viable Bifidobacterium Tetrad tablet)with 50 cases in each group by envelope drawing method.The intestinal flora,levels of serum inflammatory factors,liver function and liver fibrosis indexes,and the occurrence of adverse reactions were compared between the two groups.Results After treatment,the counts of anaerobic bacteria and aerobic bacteria in the observation group decreased and increased,respectively,more significantly than those in the control group(all P＜0.05).The levels of interleukin-10 and tumor necrosis factor-α decreased in both groups after treatment,and were significantly lower in observation group(all P＜0.05).After treatment,the levels of liver function indexes(aspartate aminotransferase,total bilirubin,alanine amino-transferase)and liver fibrosis indexes(hyaluronic acid,laminin,type Ⅲ procollagen)decreased in two groups,and the de-creases in observation group were higher than in control group(P＜0.05).There was no significant difference in th incidence of adverse reactions between the observation group and the control group(8.00％vs 12.00％,P＞0.05).Conclusion Bi-fidobacterium Tetrad adjuvant therapy can effectively reduce the levels of serum inflammatory factors,reduce the inflam-matory response of the body,and improve the intestinal flora in patients with CHB cirrhosis.
ProbioticsChronic hepatitis B cirrhosisSerum inflammatory factorsIntestinal microbiota
万方数据
维普
